Avelumab and Merkel Cell Carcinoma: Evaluating the Evidence for Causation

From General Health to Occupational Exposure

For decades, public health communication has centered on general wellness principles—balanced nutrition, routine screening, and avoidance of known carcinogens like tobacco. This broad foundation has served to educate populations about modifiable risk factors, yet it often stops short of addressing the specific exposures encountered in occupational settings. As industrial processes evolve, so too must the lens through which we examine health risks. The transition from general health science to targeted occupational concern requires a shift in focus: from population-wide advice to the unique vulnerabilities of workers handling novel therapeutic agents. In the context of mass production, where biologics and immunotherapies are manufactured at scale, the potential for unintended exposure becomes a critical consideration. One such agent is Avelumab, a monoclonal antibody approved for certain cancers. While its therapeutic use is well-documented, the question of causation in occupational settings—specifically, whether Avelumab exposure could be linked to Merkel cell carcinoma risk—demands careful scrutiny. This pivot from general health context to a specific exposure concern underscores the need for rigorous monitoring and protective measures in production environments, ensuring that the legacy of public health vigilance extends to the frontiers of pharmaceutical manufacturing.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab was the first therapeutic agent specifically approved for this indication, and its approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare but highly aggressive skin cancer with neuroendocrine differentiation, associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Evaluating the Evidence for a Causal Link

The query posits a causal link between avelumab and Merkel cell carcinoma. However, the available evidence does not support a causative relationship in which avelumab induces or causes MCC. Instead, the evidence consistently describes avelumab as a treatment for MCC, not a trigger. For example, avelumab is approved for use in metastatic MCC independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Studies on avelumab-refractory MCC describe patients whose disease progressed despite avelumab therapy, and these patients were subsequently treated with other immune checkpoint inhibitors such as ipilimumab plus nivolumab (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In one multicenter study, three out of five patients with avelumab-refractory MCC responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another retrospective study noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). These findings indicate that avelumab is used to treat MCC, and when it fails, alternative treatments are considered. Regarding mechanistic pathways, avelumab is an anti-PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune response against cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). This mechanism is intended to treat MCC, not cause it. The evidence does not describe any pathway by which avelumab could induce MCC. Instead, avelumab is known to cause immune-related adverse events due to overactivation of the immune system, such as hypercalcemia secondary to reactivation of sarcoidosis, as reported in one case (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcemia was managed with corticosteroids, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This adverse event is unrelated to the development of MCC.

Risk Context and Implications for Occupational Exposure

Risk considerations include the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved specifically for treating MCC, and its prescribing information likely includes warnings about immune-related adverse events, but not about causing MCC. For affected patients, causation-related considerations are not supported by the evidence; avelumab is not linked to causing MCC. The timeline between exposure and documented harm is relevant only in the context of treatment failure or adverse events, not causation of MCC. For example, in avelumab-refractory patients, the timeline from avelumab exposure to disease progression is documented, but this represents treatment resistance, not causation (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). In summary, the evidence does not support a causal link between avelumab and Merkel cell carcinoma. Avelumab is a treatment for MCC, and its use is associated with immune-related adverse events, but not with inducing the disease. The query's premise of causation is not grounded in the provided evidence.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel cell carcinoma?

No, the available evidence does not support a causal link between Avelumab and Merkel cell carcinoma. Avelumab is a treatment for MCC, not a cause. Studies consistently show it is used to treat MCC, and when it fails, patients may receive other therapies (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

What is the mechanism of Avelumab in treating Merkel cell carcinoma?

Avelumab is an immune checkpoint inhibitor that blocks PD-L1 on tumor cells, enhancing the immune response against cancer cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for metastatic MCC and has shown response rates up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel cell carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.